Search
Carprofen
go.drugbank.com/drugs/DB00821ApprovedVet approvedWithdrawnIt is no longer marketed for human usage, after being withdrawn on commercial grounds. … Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalOn April 29, 2024, tisotumab vedotin was granted full FDA approval. … Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours.
Desmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalAdditionally, it serves as a critical hematologic agent for the management of mild hemophilia A and von Willebrand disease (Type I) by transiently increasing levels of clotting factors [A31662, A275458 … On January 15, 2026, the FDA approved a new low-dose sublingual film formulation specifically for the treatment of nocturia in patients at high risk for fluid overload, utilizing a specialized delivery
Lactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedLactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]
Mixtures: Prismasol BO, PRISMASOL BO SOLUTIONGlycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigational[F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]
Mixtures: BOP whiteningtoothpasteEtelcalcetide
go.drugbank.com/drugs/DB12865ApprovedInvestigationalEtelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigational[L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate
Tolmetin
go.drugbank.com/drugs/DB00500ApprovedA non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.